Barclays analyst Stephanie Davis reiterated an Overweight rating and $39.00 price target on Evolent Health (NYSE: EVH).The analyst comments "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

TD Cowen Downgrades Humana (HUM) to HoldOctober 7, 2024 5:29 AM Piper Sandler Downgrades Humana (HUM) to NeutralOctober 3, 2024 9:35 AM Raymond James Reiterates Market Perform Rating on Humana (HUM)October 3, 2024 6:17 AM Wells Fargo Reiterates Overweight Rating on Humana (HUM)October 3, 2024 5:55 AM Bernstein SocGen Group Reiterates Market Perform Rating on Humana (HUM)October 3, 2024 5:52 AM